Home › Trial NCT04847050
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
- Trial IDNCT04847050
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorNational Cancer Institute (NCI)
- Enrollment19
- Start date2021-04-28
- ConditionsSolid Tumor Malignancy · Hematologic Malignancy · Leukemia · Lymphoma · Multiple Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.